← Back

Wire · operational-macro

COMP360 Psilocybin NDA Submitted to FDA for Treatment-Resistant Depression

Published

10 November 2026

Topic

operational-macro

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at hcplive.com →

◆ Verified

Fusion42 · 10 November 2026 · Fusion42 review

COMP360, a psilocybin-based treatment, has had a New Drug Application (NDA) submitted to the US FDA for treatment-resistant depression, marking a significant step in regulatory approval for psychedelic therapies in mental health.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 5 sources have reported it between 21 Oct 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

Psychedelic drug developers now face a clearer path to US market access following COMP360’s FDA NDA submission. You must prepare regulatory strategies to capitalise on emerging approval windows in mental health treatment.

◆ Coverage

5 sources · first reported 21 Oct 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

Drug DiscoveryFDA-approvalpsilocybinmental-healthdrug-approvaltreatment-resistant-depression